Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Qualigen Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CARLSBAD, CA, OCT. 12, 2025 (GLOBE NEWSWIRE) -- QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) (THE COMPANY) TODAY ANNOUNCED THE OFFICIAL LAUNCH OF C10 CRYPTOCURRENCY ASSET TREASURY (DAT) PURCHASES: WHY IS THIS PULLBACK THE GOLDEN MOMENT CXC10 HAS BEEN WAITING FOR?

QUALIGEN THERAPEUTICS ANNOUNCES THE OFFICIAL LAUNCH OF C10 CRYPTOCURRENCY ASSET TREASURY (DAT) PURCHASES: WHY IS THIS PULLBACK THE GOLDEN MOMENT CXC10 HAS BEEN WAITING FOR?

CARLSBAD, CA, OCT. 06, 2025 (GLOBE NEWSWIRE) -- QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) (THE COMPANY) TODAY ANNOUNCED A SERIES OF KEY LEADERSHIP AND GOVERNANCE CHANGES AIMED AT STRENGTHENING ITS EXECUTIVE TEAM, ENHANCING FINANCIAL TRANSPARENCY, AND SUPPORTING THE COMPANY'S NEXT PHASE OF STRATEGIC GROWTH.

QUALIGEN THERAPEUTICS (NASDAQ: QLGN) ANNOUNCES EXECUTIVES, BOARD OF DIRECTORS APPOINTMENTS AND AUDITOR TRANSITION

NEW YORK, SEPT. 30, 2025 (GLOBE NEWSWIRE) -- UNIVEST SECURITIES, LLC (UNIVEST), A MEMBER OF FINRA AND SIPC, AND A FULL-SERVICE INVESTMENT BANK AND SECURITIES BROKER-DEALER FIRM BASED IN NEW YORK, TODAY ANNOUNCED THE CLOSING OF $41 MILLION STRATEGIC INVESTMENT IN ITS CLIENT QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) (QUALIGEN THERAPERTICS), A CLINICAL-STAGE THERAPEUTICS COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR ADULT AND PEDIATRIC CANCER, FROM ITS CLIENT FARADAY FUTURE INTELLIGENT ELECTRIC INC. (NASDAQ: FFAI) (FARADAY FUTURE, FF OR COMPANY), A CALIFORNIA-BASED GLOBAL SHARED INTELLIGENT ELECTRIC MOBILITY ECOSYSTEM COMPANY.

UNIVEST SECURITIES, LLC ANNOUNCES CLOSING OF $41 MILLION STRATEGIC INVESTMENT IN CLIENT QUALIGEN THERAPEUTICS (NASDAQ: QLGN) FROM CLIENT FARADAY FUTURE (NASDAQ: FFAI)

CARLSBAD, CA, SEPT. 30, 2025 (GLOBE NEWSWIRE) -- QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) (QUALIGEN OR THE COMPANY) TODAY ANNOUNCED THE SUCCESSFUL CLOSING OF A $41 MILLION PRIVATE INVESTMENT IN PUBLIC EQUITY (PIPE) FINANCING LED BY FARADAY FUTURE INTELLIGENT ELECTRIC INC. (NASDAQ: FFAI) (FF), ALONG WITH ITS FOUNDER AND GLOBAL CO-CEO YT JIA, PRESIDENT JERRY WANG, SIGN FOUNDATION  A BLOCKCHAIN TECHNOLOGY COMPANY BACKED BY BINANCE LABS, SEQUOIA CAPITAL (US, INDIA, CHINA), IDG, AND CIRCLE, AND OTHER LEADING INVESTORS.

QUALIGEN THERAPEUTICS ANNOUNCES SUCCESSFUL CLOSING OF $41 MILLION PIPE FINANCING LED BY FARADAY FUTURE, ACCELERATING NEW BUSINESS TRANSFORMATION INTO CRYPTO

QLGN IS EXPECTED TO REBRAND AS CXC10 SOON, REFLECTING ITS NEW STRATEGIC DIRECTION AROUND CRYPTO AND WEB3 BUSINESS. LOS ANGELES, SEPT.

FARADAY FUTURE ANNOUNCES CLOSING OF STRATEGIC $41 MILLION INVESTMENT IN QUALIGEN THERAPEUTICS (NASDAQ: QLGN) TO ACCELERATE ITS DUAL-FLYWHEEL & DUAL-BRIDGE ECO STRATEGY

LOS ANGELES, SEPT. 21, 2025 (GLOBE NEWSWIRE) -- FARADAY FUTURE INTELLIGENT ELECTRIC INC. (NASDAQ: FFAI) (FARADAY FUTURE, FF OR COMPANY), A CALIFORNIA-BASED GLOBAL SHARED INTELLIGENT ELECTRIC MOBILITY ECOSYSTEM COMPANY ANNOUNCED THAT IT IS STRATEGICALLY INVESTING IN PUBLIC COMPANY QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN), WHICH WILL START A CRYPTO AND WEB3-RELATED BUSINESS. THE ANNOUNCEMENT, WHICH INCLUDED NUMEROUS COMPANY UPDATES, OCCURRED AT ITS ANNUAL 919 EVENT, HELD ON FRIDAY, SEPT. 19, AT ITS LOS ANGELES HEADQUARTERS.

FARADAY FUTURE ANNOUNCED A TOTAL STRATEGIC INVESTMENT OF $41 MILLION IN QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) DURING ITS ANNUAL 919 EVENT, FOR ITS CRYPTO BUSINESS FOCUSING ON THREE GROWTH ENGINES

LOS ANGELES AND CARLSBAD, CALIF., SEPT. 19, 2025 (GLOBE NEWSWIRE) -- FARADAY FUTURE INTELLIGENT ELECTRIC INC. (NASDAQ: FFAI) (FARADAY FUTURE, FF OR COMPANY), A CALIFORNIA-BASED GLOBAL SHARED INTELLIGENT ELECTRIC MOBILITY ECOSYSTEM COMPANY, AND QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) ("QLGN"), JOINTLY ANNOUNCED THAT THEY HAVE ENTERED INTO A SECURITIES PURCHASE AGREEMENT (THE AGREEMENT) FOR A PRIVATE INVESTMENT IN PUBLIC EQUITY (PIPE) IN QLGN'S COMMON STOCK AND PREFERRED STOCK, AND WILL START A CRYPTO AND WEB3-RELATED BUSINESS.

FARADAY FUTURE ANNOUNCES STRATEGIC $41 MILLION INVESTMENT IN QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) FOR CRYPTO BUSINESS THROUGH PIPE TRANSACTION

LOS ANGELES AND CARLSBAD, SEPT. 19, 2025 (GLOBE NEWSWIRE) -- FARADAY FUTURE INTELLIGENT ELECTRIC INC. (NASDAQ: FFAI) (FARADAY FUTURE, FF OR COMPANY), A CALIFORNIA-BASED GLOBAL SHARED INTELLIGENT ELECTRIC MOBILITY ECOSYSTEM COMPANY, AND QUALIGEN THERAPEUTICS, INC. (NASDAQ:QLGN) ("QLGN"), JOINTLY ANNOUNCED THAT THEY HAVE ENTERED INTO A SECURITIES PURCHASE AGREEMENT (THE AGREEMENT) FOR A PRIVATE INVESTMENT IN PUBLIC EQUITY (PIPE) IN QLGN'S COMMON STOCK AND PREFERRED STOCK, AND WILL START A IN CRYPTO AND WEB3-RELATED BUSINESS.

FARADAY FUTURE ANNOUNCES STRATEGIC $41 MILLION INVESTMENT IN QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) F FOR CRYPTO BUSINESS THROUGH PIPE TRANSACTION

CARLSBAD, CA, JULY 28, 2025 (GLOBE NEWSWIRE) -- QUALIGEN THERAPEUTICS, INC. (NASDAQ:QLGN) ("QUALIGEN" OR THE "COMPANY"), A LIFE SCIENCES COMPANY FOCUSED ON DEVELOPING PLATFORM TREATMENTS FOR ADULT AND PEDIATRIC CANCERS WITH THE POTENTIAL FOR ORPHAN DRUG DESIGNATIONS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO DEFINITIVE SECURITIES PURCHASE AGREEMENTS WITH SEVERAL INSTITUTIONAL AND ACCREDITED INVESTORS FOR THE SALE OF ITS SERIES A-3 PREFERRED STOCK. THE PRIVATE PLACEMENT CLOSED ON JULY 28, 2025. THE COMPANY ISSUED AND SOLD AN AGGREGATE OF 4,500 SHARES OF SERIES A-3 PREFERRED STOCK, WITH A STATED VALUE OF $1,000 PER SHARE, FOR AGGREGATE GROSS PROCEEDS OF $4.5 MILLION, BEFORE DEDUCTING PLACEMENT AGENT FEES AND OTHER OFFERING EXPENSES. THE SERIES A-3 PREFERRED STOCK IS INITIALLY CONVERTIBLE INTO AN AGGREGATE OF 1,607,143 SHARES OF COMMON STOCK OF THE COMPANY AT A CONVERSION PRICE OF $2.80 PER SHARE, SUBJECT TO ADJUSTMENT IN ACCORDANCE WITH THE TERMS OF THE SERIES A-3 PREFERRED STOCK CERTIFICATE OF DESIGNATION.

QUALIGEN THERAPEUTICS ANNOUNCES $4.5 MILLION PRIVATE PLACEMENT OF SERIES A-3 CONVERTIBLE PREFERRED STOCK

CARLSBAD, CALIF., JULY 16, 2025 (GLOBE NEWSWIRE) -- QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) (THE COMPANY OR QUALIGEN) IS ANNOUNCING AN UPDATE ON PATENTS GRANTED IN THE FIRST SIX MONTHS OF 2025. THE PATENT IS TITLED SUBSTITUED NAPHTHALENE DIIMIDES AND THEIR USE. THE PATENT IS FOR THE DRUG, WHICH WAS DEVELOPED BY PROFESSOR STEPHEN NEIDLE AND HIS TEAM AT THE UNIVERSITY COLLEGE OF LONDON, AND IS LICENSED BY QUALIGEN THERAPEUTICS, QN-302. THESE PATENTS COVER THE PRODUCT AND THEIR METHODS OF MANUFACTURING.

QUALIGEN GRANTED NEW PATENTS COVERING 25 COUNTRIES

CARLSBAD, CALIF., MAY 19, 2025 (GLOBE NEWSWIRE) -- QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) (THE COMPANY) ANNOUNCED TODAY THAT IT RECEIVED AN EXPECTED DEFICIENCY NOTIFICATION LETTER FROM THE LISTING QUALIFICATIONS STAFF OF THE NASDAQ STOCK MARKET LLC ("NASDAQ") ON MAY 19, 2025 (THE "NOTICE"). THE NOTICE INDICATED THAT THE NASDAQ HEARINGS PANEL (THE PANEL) WILL CONSIDER THE COMPANY'S FAILURE TO TIMELY FILE ITS QUARTERLY REPORT ON FORM 10-Q FOR THE PERIOD ENDED MARCH 31, 2025 AS AN ADDITIONAL BASIS FOR DELISTING THE COMPANY'S SECURITIES FROM THE NASDAQ STOCK MARKET.

Qualigen Therapeutics, Inc.

QLGN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Qualigen Therapeutics, Inc.

QLGN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

QLGN